Mon.Dec 25, 2023

article thumbnail

In a slow year for enterprise tech M&A, there were few standout deals

TechCrunch: M&A

It was a slow year in enterprise technology M&A, and the total was the second lowest since we started compiling the data in 2018. © 2023 TechCrunch. All rights reserved. For personal use only.

M&A 252
article thumbnail

The option income ETF craze has started to cool, but Wall Street is betting it's here to stay

CNBC: Investing

Funds like the JPMorgan Premium Income ETF (JEPI) may be less attractive to investors during big rallies, but can still deliver solid payouts.

Funds 138
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Banks shed 60,000 jobs in one of worst years for cuts since financial crisis

Financial Times - Banking

Trend set to continue over coming year amid subdued dealmaking and listing activity

Bank 112
article thumbnail

Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024

CNBC: Investing

Oprah Winfrey has changed her mind on weight loss drugs and others have, too. What's ahead for the category in 2024.

Trading 128
article thumbnail

Navigating the Future: Generative AI, Application Analytics, and Data

Generative AI is upending the way product developers & end-users alike are interacting with data. Despite the potential of AI, many are left with questions about the future of product development: How will AI impact my business and contribute to its success? What can product managers and developers expect in the future with the widespread adoption of AI?

article thumbnail

???????????????????????????????????????

Global Newswire by Notified: M&A

此次拟议收购将进一步扩充阿斯利康公司的细胞疗法管线,为其增添一款处于临床阶段、针对多种恶性血液肿瘤和自身免疫性疾病的BCMA/CD19自体CAR-T细胞疗法,以及专有的细胞疗法FasTCAR生产技术平台 亘喜生物股东将在交易完成时获得亘喜生物普通股每股$2.00 (相当于每股美国存托股份 (ADS).

81